chrisvoncsefalvay/vaers-outcomes huggingface dataset:
developed a mental delay; fatigue; weakness; shortness of breath; rapid pulse; chest pain; This is a spontaneous report from a Pfizer-sponsored program, via a contactable physician.   A 28-year-old female patient received the second dose of the bnt162b2 (BNT162B2), via an unspecified route of administration on an unspecified date at a single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously received the first dose of the bnt162b2 on an unknown date at a single dose for covid-19 immunisation.  On an unknown date, two weeks after the bnt162b2 vaccine, the patient developed a mental delay, fatigue, weakness, shortness of breath, rapid pulse, and chest pain. The events were further described as: patient developed fatigue, weakness, mental delay, shortness of breath, rapid pulse and chest pain (resembled pericarditis, cardiac workup negative as of now) 2 weeks after her second bnt162b2 vaccine. Per patient similar to POTS Syndrome (as reported). The patient underwent lab data and procedures which included cardiac workup: negative on an unknown date. The clinical outcome of all events was unknown.   The batch/lot number for the vaccine, bnt162b2, was not provided and will be requested during follow up.; Sender's Comments: The contributory role of the suspect product bnt162b2 (COMIRNATY), to reported events is possible based on temporal association and known profile of the product.
Patient had itching immediately after the second dose of the mRNA Moderna COVID-19 vaccine. She took some Benadryl that she had and when she continued to itch, informed the medical team. She was evaluated and given she continued to have generalized itching, feeling of swollen tongue and started to cough, IM epinephrine was administered and 911 was called.  Patient's symptoms resolved immediately after the Epi injection and she was transferred to hospital by EMS in stable condition.   She had no reaction to the first dose of the vaccine.
Information has been received from a registered nurse concerning a patient (age and gender not reported), with concomitant medications, pertinent medical history and drug reactions/allergies unspecified, who on 22-JUL-2008 was vaccinated with a dose of PNEUMOVAX (lot # 659149/1383U), 0.5 ml, intramuscularly (IM). Subsequently, on an unspecified date, the patient experienced soreness, redness and heat at the injection site. The patient sought unspecified medical treatment from the physician and was reported to be recovering. This is one of several reports from the same source. Additional information has been requested.
Bad migraine; Nausea; Tingling sensation in the face, head, and upper temples; Cold sensation in the face and head; Headache; This is a spontaneous report from a contactable consumer (patient). A 34-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; solution for injection; lot number: EW0196), via an unspecified route of administration, administered in the left arm on 25Jun2021 (at the age of 34-years-old) as dose 1, single for COVID-19 immunization. The patient has no relevant medical history and has no concomitant medications. The patient has no prior vaccinations within 4 weeks of the COVID vaccine. On 25Jun2021 (the day of vaccination), the patient received the first dose of BNT162B2 at a hospital. The patient was fine after the vaccination. On 30Jun2021 (5 days after the vaccination), the patient started to have bad headaches with subsequent mild headache, nausea, tingling/cold sensation in the face, head, and upper temples for about a week and a half. The patient had never had this type of headache prior. The patient almost went to the emergency room. On 03Jul2021, the patient experienced a bad migraine. The patient has been on Tylenol and Excedrin migraine on hand ever since. The patient wanted to schedule an appointment with the neurologist, but they were busy. The patient mentioned that she does not plan on getting the second dose because these side effects were frightening to her. The outcome of events headache and migraine was recovering while the outcome of the remaining events was not recovered.  Follow-up attempts are completed. No further information is expected.
This spontaneous report as received from a physician (Local Reference Number#US12-056809) refers to a female patient of unknown age who was a junior in high school with no past medical history of note. The patient was vaccinated with first dose of GARDASIL (Lot #, dose, route unspecified) in August 2012. She had tolerated vaccines in the past without incident. Until recently, she took no medications but had been prescribed ABILIFY and CELEXA in recent weeks. The patient experienced nausea, insomnia, anxiety and depression starting within 24 hours of receiving her first dose of GARDASIL in August 2012. This was followed within a short time (weeks) by the onset of visual disturbance (blurry vision) which had persisted. A work-up by ophthalmology including MRI had not revealed any abnormalities. Physician did mention that his daughter might be having twitching of the extra ocular muscles, causing her to squint to be able to focus her vision. Patient had missed a fair amount of school which exacerbates her anxiety and depression. No treatment information was reported. The outcome of visual disturbance (blurry vision) was reported as not recovered/not resolved. The outcome of all the other events were unknown. Additional information has been requested.
chills; fever; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CHILLS (non-serious), outcome "unknown", described as "chills"; PYREXIA (non-serious), outcome "unknown", described as "fever".  Additional Information: This consumer reported in response to Non-HCP telephonic activity in cross-referenced case that included Phone-Out 11:12 AM: 2nd attempt by phone to consumer to obtain follow-up information contained on consumer questionnaire. Consumer did not want to provide mailing address but agree to provide e-mail address instead. She also stated in all three shot she had chills and fever, but with covid booster shot she had a rash like hives for a week and a half.  Follow-up attempts completed. No further information is expected.
PAIN AT INJECTION SITE; FEVER; CHILLS; BODY ACHE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, and batch number: UNKNOWN expiry: UNKNOWN) .5 ml, administered on 07-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On MAR-2021, the subject experienced pain at injection site. On MAR-2021, the subject experienced fever. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced body ache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the pain at injection site, fever, chills and body ache was not reported. This report was non-serious.
Diarrhea; Severe abdominal pain; Spontaneous report received on 05DEC2019.  A male consumer reported he had severe abdominal pain (PT: Abdominal pain) and diarrhea (PT: Diarrhoea), while being on oral Vivotif for typhoid fever. On 03DEC2019, the consumer took the first dose of Vivotif and developed severe abdominal pain, which was resolved completely by the next day. On 05DEC2019, he took his second dose in the morning about 08:00 am, one hour prior to eating. On the same day at 01:00 pm, he had severe abdominal pain and diarrhea, so he was on the toilet for all the day. He stated that the pain was worse than the first day he took the first dose. The pain persisted for about six hours. Action taken with Vivotif with respect to the reported events was unknown. The reported events were not resolved at the time of report.  Company Comment: A consumer experienced severe abdominal pain and diarrhea after a few hours of Vivotif doses. Considering the potential of Vivotif to cause abdominal pain, diarrhea and case information, the causality of both the events is assessed as possible with Vivotif.; Sender's Comments: A consumer experienced severe abdominal pain and diarrhea after a few hours of Vivotif doses. Considering the potential of Vivotif to cause abdominal pain, diarrhea and case information, the causality of both the events is assessed as possible with Vivotif.
Within 24 hours: soreness and stiff muscle around the injection site. 48 hours: red eye and stuffiness  72 hours: swimmer's ear accompanied by dizziness, major headache at the top of neck, fever, light sensitivity, a few hives, 96 hours: "pox" on  upper back and arms. Treatment: TYLENOL, pseudoephedrine, BENADRYL.
Body ache fever nausea vomiting diarrhea 11/11/20 to 11/22/20
10cm x 12cm oval-shaped erythematous patch, warm to touch at site of vaccine on (R) upper, lateral arm. Started on cephalexin 500mg tid x 10d.
Myalgia, CoughWheeze worsening of asthma, fatigue Narrative:  Prior to getting the COVID vaccine the patient's asthma was well controlled. Since getting the second dose of Moderna vaccine on 1/26/21 the patient's asthma has been severe. She reports 4 asthma attacks per week. She does a daily nebulizer treatment, and uses her rescue inhaler 5 times a day on average. She has shortness of breath with exertion. She has also experienced myalgia and fatigue since January. The patient has required EMS at least once due to an asthma attack.
PATIENT WAS VACCINATED WITH A 2ND DOSE OF JANSSEN VACCINE. NO ADVERSE REACTION REPORTED.
her tongue was hanging out; couldn't breathe; This spontaneous case was reported by a patient family member or friend and describes the occurrence of TONGUE DISCOMFORT (her tongue was hanging out) and DYSPNOEA (couldn't breathe) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced TONGUE DISCOMFORT (her tongue was hanging out) and DYSPNOEA (couldn't breathe). At the time of the report, TONGUE DISCOMFORT (her tongue was hanging out) and DYSPNOEA (couldn't breathe) outcome was unknown. The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown. No concomitant medication reported.  The reporter stated that she had to take her daughter (Patient) to ER after receiving the COVID-19 vaccine (unknown if vaccine administered was Moderna).  No treatment medication details reported.   Reporter did not allow further contact
Had vaccine 2/10/2021, with no bad side effects at the time, just upper left arm dull pain for 2 days.  In the last two weeks, I've had intermittent cramping (arms, legs, back) after eating.    Something aggravated my IBS-C and I believe that could be the vaccination.   The cramping is still happening but not continuously.  In the last week, I've had tingling or burning twinges on the outside of my right thigh, too, on and off.   Might have been connected with heavy keys in my right front pants pocket and a cell phone on my belt near the thigh.   The same meals that cause cramping seem to cause the tingling, but I don't know if there is a connection.  The tingling may be from Meralgia paresthetica.
This 14-year-old patient inadvertently received 0.25mL of Moderna approved for 18+. Patient observed for 15 minutes with no adverse reactions. This was the third dose for the patient. The first 2 doses were Pfizer (purple cap) for 12+.
Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided. Treatment medications were not provided.
Sore throat; stuffy nose; tiredness; This is a spontaneous report from contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8735), via an unspecified route of administration in the left arm on 29Mar2021 at 16:15 (at the age of 29-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not any medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 30Mar2021 at 16:00, the patient experienced sore throat, stuffy nose and tiredness. The events resulted in doctor or other healthcare professional office or clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events sore throat, stuffy nose and tiredness were not recovered.  No follow-up attempts are needed. No further information is expected.
Severe headache to the point where even my teeth hurt, nausea, dizziness, ocular migraines.
Red, swelling, hives at site of injection approx 2-3 minutes after injection.
Heart was little bit racing; This is a spontaneous report from a contactable physician report for self. This 50-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 30Dec2020 in the morning at single dose for COVID-19 immunization. Medical history included borderline hypertension. There were no concomitant medications. Patient probably took some medication in the past but nothing now. The patient took the vaccine in the morning on 30Dec2020, after took the vaccine he sit in the room for monitoring for 15 minutes, after 1 or 2 minutes patient felt like heart was little bit racing, he didn't have any other problems like no shortness of breath, no difficulty breathing, no rash or anything like that and he took some bottled water and started drinking, few minutes later, it may have lasted for 5 minutes, it subsided. No emergency room or physician office visited. The patient's question was whether he could take second shot or not which is probably given in 3 weeks. The outcome of event was recovered on 30Dec2020.  No follow-up attempts are possible. Information about lot/batch number could not be requested. No further information is expected.
Hospitalized due to altered mental status post dialysis COVID positive treated with IV remdesivir. Immunosuppressed with tacrolimus and prednisone post kidney and pancreas transplant
Pt states today 1/28/19 that his arm still hurts from the SHINGRIX vaccine given on 8/26/18. He hasn't seen a MD about it, or taken any meds for it. On a scale of 1 to 10 (10 being most severe) he would describe the pain as 2 or 3.
terrible sometimes unbearable pain in my legs, hips and knees; terrible sometimes unbearable pain in my legs, hips and knees; barely walk at time; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, I took the first 2 Covid shots with no problem), for COVID-19 Immunization, reaction(s): "no problem"; Covid-19 vaccine (Dose 2, I took the first 2 Covid shots with no problem), for COVID-19 Immunization, reaction(s): "no problem". The following information was reported: PAIN IN EXTREMITY (non-serious), ARTHRALGIA (non-serious), outcome "not recovered" and all described as "terrible sometimes unbearable pain in my legs, hips and knees"; GAIT DISTURBANCE (non-serious), outcome "not recovered", described as "barely walk at time".  Additional Information: Patient took the first 2 Covid shots with no problem. Patient took the third one and ever since have terrible sometimes unbearable pain in patient's legs, hips and knees. Patient sometimes wish somebody would amputate them they hurt so badly. Stated this shot has ruined patient's life. Patient can barely walk at times.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
hair is falling; muscle weakness; fever; Was in bed all the time; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (hair is falling), MUSCULAR WEAKNESS (muscle weakness), PYREXIA (fever) and FATIGUE (Was in bed all the time) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 030A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in December 2020.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced ALOPECIA (hair is falling), MUSCULAR WEAKNESS (muscle weakness), PYREXIA (fever) and FATIGUE (Was in bed all the time). At the time of the report, ALOPECIA (hair is falling), MUSCULAR WEAKNESS (muscle weakness), PYREXIA (fever) and FATIGUE (Was in bed all the time) outcome was unknown.       Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-090231 (Patient Link).
approx 6hr p/vax T103;lt eye redness & matting & watering;went to ER;took med;returned for hosp-ulcerative cornea dx per MD;
Information has been received from a registered nurse concerning a 51 year old female with a "sinus history" who on approximately 07/03/01 was vaccinated with pneumococcal vaccine 23 polyvalent. Subsequently, the patient began to experience fatigue and malaise. Unspecified medical attention was sought. Additional information has been sought.
pt devel limp in rt leg 1 day p/vax;pt exp no impairment of activities;
Approx 22 hours after vaccine dose I experienced shortness of breath, nausea, full feeling in chest, chills, extreme fatigue, headache, body aches, diarrhea and a fever of 101 degrees. These initial symptoms lasted approx 24 hours.  The headache, nausea, and some fatigue lasted another 72 hours. Also my arm where I had injection was extremely sore for approx 5 days.
Pt complains of chest pressure and inability to take a deep breath with a feeling of flushing with the vaccine
Myalgias, fatigue, subjective fever, erythematous at injection site second day which has increased in size.
pt recvd vax;devel fever 101;myalgia,ha & noc sweats;stiff neck,swollen glands lt axilla;4th wk began to abate,devel pain over both eyes;c/o blurred vision,saw ophtalmologist who saw a "central blind spot in rt eye" dx:papilledema,cause vax
Headache; chills; Nausea; This is a spontaneous report received from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in left arm on 22Mar2021 at 18:30 (at the age of 43-years-old) as single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included VITA FUSION GUMMIES and FLO VITAMINS. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Mar2021, the patient experienced headache, chills and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache, chills and nausea was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Approximately 1 week after the Pfizer dose I had a small lump and soreness over my right flank at the kidney level.  Over the next two days that pain migrated to my right buttock and radiated down my right leg.  With full weight applied to my right leg the leg had weakness and would occasionally buckle.  I am due for my second injection but am considering not taking the second injection fearing permanent nerve involvement.  As of today 2/23 the pain in my right leg and buttocks is lessened but still present.
chills, rigors, muscles and joints aches, nausea, vomiting, fatigue, sweats lasting until morning of 09/30/2022
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) in a 63-year-old male patient who received mRNA-1273 (Spikevax) (batch no. O70H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine used).      Concomitant medications details were not reported by the reporter.  Reportedly, the number of patients at facility that received this Moderna vaccine between 08-Apr-2022 and 15-Dec-2022. Additionally, In the second list, reporter discovered a past lot that had also been expired and administered to patients with batch number as 065F21A.    Treatment details were not reported by the reporter.
Site: Itching at Injection Site-Severe, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Flushed / Sweating-Medium, Additional Details: pt had sever rash on body
While sitting in the recovery area, patient said he felt "nervous" and sat on the floor. Upon assessment, patient was hot to touch. BP 120/82 P59 SpO2 99% room air. Patient said, "I'm dehydrated." Gatorade water given and cool compresses applied to face and neck. Additional monitoring done.  Denies EMS evaluation. Patient ambulated from facility with girlfriend. No s/sx of distress noted.
Family describe redness after vaccine at site (left arm) and area increased up to 3 x 4 cm on 4/14/03 at time of re-evaluation - MD Rx Keflex  250 TID for 10 days and Atarax for swelling.